- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01690767
A Study to Assess the Ability of 2% Lidocaine Gel to Reduce the Discomfort of Urethral Catheterization
A Randomized Blinded Controlled Trial of 2% Lidocaine Gel Compared to Standard of Care in Children Undergoing Urethral Catheterization
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An estimated 10% of children 0-24 months of age that present to the emergency department (ED) with fever and/or vomiting have a urinary tract infection (UTI). An accurate diagnosis of a UTI ensures timely and appropriate treatment given to reduce the risk of renal scarring, which is the greatest in this age group. To ensure diagnostic accuracy, urethral catheterization is the preferred method to obtain a urine sample from a young child. In contrast to adults, most children do not receive local analgesia for urethral catheterization; despite growing recognition that children experience avoidable pain and discomfort during invasive procedures.
Following informed consent, participants will be randomized by block randomization in a concealed fashion to receive either topical and intraurethral 2% lidocaine or standard of care using a computerized random number generator. The research nurse will access a sequentially numbered, opaque sealed envelope that will contain the participant's group assignment. No adjunctive analgesic methods will be used. A research pharmacist will prepare 2% lidocaine gel in a 3 cc syringe attached to a 24 gauge angiocath. Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc, respectively (2).
The entire procedure will be videotaped and participants pain will be scored using a brow bulging score and visual analogue scale by independent, blinded raters.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6C 2V5
- Children's Hospital, London Health Sciences Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- children 0-24 months of age presenting to the emergency department requiring a urethral catheterization to obtain a urine specimen
Exclusion Criteria:
- unstable
- external genitourinary anomalies
- lidocaine allergy and
- previous catheterization within 24 hours
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Topical and intraurethral 2% lidocaine
2% lidocaine gel will be applied for 5 minutes to the external urethral opening.
This will be followed immediately by 2% lidocaine gel administration into the urethra using a 24 gauge angiocath for 5 minutes prior to catheterization for urine specimen collection.
Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc, respectively.
|
Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
Other Names:
|
Active Comparator: Standard of care
According to standard nursing practice, the urethra will be catheterized without anaesthetic gel but using lubricant gel only.
Intervention is Health Care Lubricating Jelly.
|
Non-medicinal lubrication gel
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brow Bulging Score
Time Frame: 30 seconds post intervention compared to baseline
|
The presence of brow bulging will be scored in 2-second intervals for the first 30 seconds for each of the six phases.
The percentage of time that brow bulging is observed will then be calculated for each phase.
|
30 seconds post intervention compared to baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Facial grimacing score
Time Frame: 30 seconds post intervention compared to placebo
|
The presence of brow bulging, nasolabial furrowing and eyes squeezing shut will be scored in 2-second intervals for the first 30 seconds for each of the six phases.
The percentage of time that all three of these features is observed will then be calculated for each phase.
|
30 seconds post intervention compared to placebo
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Naveen Poonai, MD, FRCPC, Western University, Canada
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Urologic Diseases
- Urinary Tract Infections
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
- 17770
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infection
-
Gloucestershire Hospitals NHS Foundation TrustUnknownCatheter Infection | Urinary Tract Infection in Pregnancy | Urinary Tract Infection Following Delivery
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedUrinary Tract Infection | Recurrent Urinary Tract InfectionCanada
-
National Institute of Allergy and Infectious Diseases...TerminatedUrinary Tract InfectionUnited States
-
University Of PerugiaUnknownUrinary Tract Infection
-
NanovibronixShaare Zedek Medical CenterUnknownUrinary Tract InfectionIsrael
-
Hadassah Medical OrganizationUnknown
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)UnknownUrinary Tract InfectionCanada
-
Impatients N.V. trading as myTomorrowsInmunotek S.L.No longer availableUrinary Tract Infections | Bladder Infection | Recurrent Urinary Tract Infection | Urinary Tract Infection Bacterial | Chronic Urinary Tract InfectionCzechia, Denmark, Serbia, France, Germany, Turkey, Belgium, Finland, Luxembourg, Netherlands, Norway, Romania, Slovakia, Slovenia, Sweden
-
Hospital de Clinicas de Porto AlegreUnknownUrinary Tract Infection | Respiratory Tract InfectionBrazil
-
Bactiguard ABRehab Station StockholmCompletedComplications; Catheter, Urinary Infection or InflammationSweden
Clinical Trials on 2% lidocaine gel
-
Second Xiangya Hospital of Central South UniversityWithdrawn
-
Oregon Health and Science UniversityCompleted
-
Sol-Gel Technologies, Ltd.TerminatedBasal Cell Nevus SyndromeUnited States, France, Belgium, Denmark, Germany, Italy, Netherlands, Spain, United Kingdom
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
University of OklahomaWithdrawnPain Perception | PhlebotomyUnited States
-
Women and Infants Hospital of Rhode IslandSociety of Family PlanningCompleted
-
Atlantic Health SystemCompletedOveractive Bladder | Urinary Incontinence | Voiding DisordersUnited States
-
Pharma Holdings ASCTC Clinical Trial Consultants ABCompletedNasal Decolonization of Staphylococcus AureusSweden
-
Taro Pharmaceuticals USACompleted